The International Longevity Alliance will stage a public march in Madrid on 1 October, moving from the Royal National Academy of Medicine of Spain to Madrid City Hall, with readings of the Madrid Longevity Declaration at four stops. The declaration calls for formal recognition of aging as a target for medical intervention and increased research funding. The event coincides with the International Longevity Summit and reframes geroscience as a matter of public policy rather than closed scientific discussion.
Key Points
- Madrid march routes from medical academy to city hall, 1 October
- Declaration demands aging be recognized as intervention target
- Madrid life expectancy reached 85.7 years in 2024
Longevity Analysis
Geroscience has largely circulated among researchers, clinicians and investors; moving the argument toward legislative and municipal institutions tests whether the case holds outside that audience. The distinction organizers press — years accumulated versus years spent in reasonable health — is the operative one, since extended lifespan paired with multimorbidity and frailty places entirely different demands on regenerative capacity, musculoskeletal integrity and care systems. Advocacy cannot substitute for evidence on whether aging itself constitutes a treatable condition, but research funding and preventive care priorities are set in the political arena, and sustained public pressure is how those priorities shift.
Original published by Longevity.Technology, by Eleanor Garth.